sdü tıp fak derg Medical Journal of Süleyman Demirel University 2602-2109 Süleyman Demirel Üniversitesi 10.17343/sdutfd.605500 Clinical Sciences Klinik Tıp Bilimleri Meme Kanserinde Moleküler Alt Tiplerin Klinikopatolojik Özelliklerle İlişkisi The relationship of the molecular subtypes with the clinicopathological features in breast cancer Bozkurt Kemal Kürşat SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, TIBBİ PATOLOJİ ANABİLİM DALI Durak Özlem T.C. SAĞLIK BAKANLIĞI KAMU HASTANELER BİRLİĞİ KASTAMONU DEVLET HASTANESİ TIBBİ PATOLOJİ BÖLÜMÜ Çiriş İbrahim Metin SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, TIBBİ PATOLOJİ ANABİLİM DALI Kapucuoğlu Nilgün KOÇ ÜNİVERSİTESİ, TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, TIBBİ PATOLOJİ ANABİLİM DALI Devrim Tuba KIRIKKALE ÜNİVERSİTESİ, TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, TIBBİ PATOLOJİ ANABİLİM DALI 06 01 2020 27 2 160 165 08 15 2019 09 03 2019 Copyright © 1994, Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi 1994 Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

Amaç: Memekanserinde, moleküler alt tiplerin, klinikopatolojik özellikler (tanı yaşı,histolojik tip, histolojik derece, pT ve pN evreleri) ile ilişkilerinin tespit edilmesiamaçlanmıştır.Gereç ve Yöntem: Çalışma grubu 194 kadın memekanseri içermekteydi. Süleyman Demirel Üniversitesi Tıp Fakültesi TıbbiPatoloji Anabilim Dalı arşivi taranarak 2010-2015 yılları arasında meme kanseritanısı verilmiş olgulara ait biyopsi ve radikal meme rezeksiyonu materyallerininpreparatları tekrar incelendi. Olguların immünhistokimyasal ER, PgR, HER2 veKi67 boyalı preparatları tekrar değerlendirilerek moleküler alt tiplendirme yapıldı. Bulgular: Tümörmoleküler alt tipleri; %47,4 olguda Luminal A [ER ve/veya PgR(+)/HER2(-)/Ki67 ≤ %14], %25,8 olguda Luminal B [ER ve/veya PgR(+)/HER2(+) veya (-) /Ki67> %14], %13,4 olguda HER2 overeksprese [ER(-)/PgR(-)/HER2(+)] ve %13,4 olguda ise üçlü negatif [ER(-)/PgR(-)/HER2(-)] idi. Tümörderecesi ve aksiller lenf nodu metastazı; Luminal B, HER2 overeksprese ve üçlünegatif tümörlerde Luminal A tümörlere göre daha yüksek izlendi. Luminal tiptümörlerle karşılaştırıldığında, HER2 overeksprese ve üçlü negatif tümörlerdelenfovasküler invazyon oranı anlamlı olarak daha fazla idi. Sonuç: Heterojenbir tümör grubu olan meme kanserlerinde evre ve diğer iyi bilinen klinikopatolojiközelliklerin yanında moleküler alt tiplendirmenin de hasta yönetimi içinfaydalı bilgiler verebileceği sonucuna varılmıştır.

Objective:To determine therelationship between the molecular subtypes and the clinicalopathologicalfeatures (age at the diagnosis, histological type, histological grade, pT and pNstages) in breast cancer.Materials and Methods: The studypopulation included 194 women with breast carcinoma, who were diagnosed between2010 and 2015. The slides of the cases in the archive of the Süleyman DemirelUniversity Faculty of Medicine Department of Pathology were reevaluated.Immunohistochemical ER, PgR, HER2 and Ki67 stained slides were used to perform themolecular subtyping.Results: Among thecases molecular subtypes were; Luminal A [ER and/or PgR(+)/HER2(-)/Ki67 ≤14%] in 47.4% of cases, Luminal B [ERand/or PgR(+)/HER2(+) or (-) /Ki67 > 14%] in 25.8% of cases, HER2overexpressing [ER(-)/PgR(-)/HER2(+)] in 13.4% of cases, and triplenegative [ER(-)/PgR(-)/HER2(-)] in 13.4% of the cases, respectively.Tumor grade and axillary lymph node metastasis in Luminal B, HER2overexpressing and triple negative tumors were significantly higher than theywere in Luminal A tumors. Lymphovascular invasion rate was significantly higherin HER2 overexpressing and triple negative tumors compared to Luminal typetumors.Conclusions: It was concluded that the molecular subtyping of the breast carcinoma, whichis a heterogeneous tumor group, can give important information for themanagement of the cases along with the stage and other well-known clinicopathologicalfeatures.

 Meme kanser moleküler alt tip immünhistokimya Breast cancer molecular subtype immunohistochemistry Petersen NV, Ramskov S, Andersen RS, Met Ö, Straten PT, Bentzen AKK, et al. T-cell recognition of breast cancer antigens. Proceedings of the 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2):Ab.nr B036. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008;14(16):15. Prat A , Pineda E,Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 2015;24(2):26-35. Dias K, Dvorkin-Gheva A, Hallett RM, Wu Y, Hassell J, Pond GR, et al. Claudin-Low Breast Cancer; Clinical & Pathological Characteristics. PLoS One. 2017;12(1):e0168669. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breastcancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Annals of Oncology 2011;22:1736-1747. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412-424. Ni YB, Tsang JY, Chan SK, Tse GM. A novel morphologic-molecular recurrence predictive model refines traditional prognostic tools for invasive breast carcinoma. Ann Surg Oncol. 2014;9:2928-2933 Tenea-Cojan TS, Georgescu CV, Corici OM, Voinea B, Georgescu DM, Vidrighin C, et al. Histopathological study on conservatively operated breast carcinomas. Curr Health Sci J. 2016;42(3):269-282. Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, et al. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res. 2010;12(3):R42. Cherbal F, Gaceb H, Mehemmai C, Saiah I, Bakour R, Rouis AO, et al. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study. Breast Dis. 2015;35(2):95-102. Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 2001;1:37-45. Kamranzadeh H, Ardekani RM, Kasaeian A, Sadighi S, Maghsudi S, Jahanzad I, et al. Association between Ki-67 expression and clinicopathological features in prognosis of breast cancer: A retrospective cohort study. J Res Med Sci 2019;24:30. Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, et al. High Ki-67 Expression and low progesterone receptor expression could ındependently lead to a worse prognosis for postmenopausal patients with estrogen receptor-positive and HER2-negative breast cancer. Clin Breast Cancer 2015;15(3):204-211. Caldarella A, Buzzoni C, Crocetti E, Bianchi S, Vezzosi V, Apicella P, et al. Invasive breast cancer: a significant correlation between histological types and molecular subgroups. J Cancer Res Clin Oncol 2013;139(4):617-623. Garrido-Castro AC, Lin NU, Polyak K. Insights into Molecular Classifi cations of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment, American Association for Cancer Research, 2019;doi: 10.1158/2159-8290.CD-18-1177. Van Calster B, Vanden Bempt I, Drijkoningen M, Pochet N, Cheng J, Van Huffel S, et al. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER2 status: triple positive tumours are more likely lymph node positive. Breast Cancer Res Treat 2009;113(1):181-187. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006;37(9):1217-1226.